UGT1A1genotype-dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulation

A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study

(2014) A. Thomas et al.   CLINICAL CANCER RESEARCH

Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers

(2014) Richard B. Horenstein et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Histone deacetylase inhibitor-mediated cell death is distinct from its global effect on chromatin

(2014) Victoria L. Luchenko et al.   Molecular Oncology

UGT1A1 Gene Polymorphisms and the Toxicities of FOLFIRI in Chinese Han Patients with Gastrointestinal Cancer

(2013) Chen-fei Zhou et al.   Anti-Cancer Agents in Medicinal Chemistry

LC–MS/MS assay for the quantitation of the HDAC inhibitor belinostat and five major metabolites in human plasma

(2013) Brian F. Kiesel et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Glucuronidation by UGT1A1 Is the Dominant Pathway of the Metabolic Disposition of Belinostat in Liver Cancer Patients

(2013) Ling-Zhi Wang et al.   PLoS One

Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group

(2012) Winnie Yeo et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial Tumors

(2011) Giuseppe Giaccone et al.   JOURNAL OF CLINICAL ONCOLOGY

Genetic variation in UGT1A1 typical of Gilbert syndrome is associated with unconjugated hyperbilirubinemia in patients receiving tocilizumab

(2011) Janet S. Lee et al.   Pharmacogenetics and Genomics

Combined effect of regulatory polymorphisms on transcription of UGT1A1 as a cause of Gilbert syndrome

(2010) Katsuyuki Matsui et al.   BMC GASTROENTEROLOGY

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours

(2010) U Lassen et al.   BRITISH JOURNAL OF CANCER

Handling Data Below the Limit of Quantification in Mixed Effect Models

(2009) Martin Bergstrand et al.   AAPS Journal

Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and Solutions

(2009) Radojka M. Savic et al.   AAPS Journal

Epigenetic Modifiers: Basic Understanding and Clinical Development

(2009) R. L. Piekarz et al.   CLINICAL CANCER RESEARCH

Monitoring the effect of belinostat in solid tumors by H4 acetylation

(2008) LENA MARQUARD et al.   APMIS

A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors

(2008) N. L. Steele et al.   CLINICAL CANCER RESEARCH

Likelihood based approaches to handling data below the quantification limit using NONMEM VI

(2008) Jae Eun Ahn et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS